Prophylix AS is a Norwegian biotech company developing orphan drugs for the prevention of life-threatening or chronically disabling intracranial bleeding in fetuses due to fetal and neonatal alloimmune thrombocytopenia (FNAIT). The lead drug NAITgam contains specific IgG antibodies derived from plasma donated by women with a history of FNAIT in their fetus or newborn. The NAITgam is developed within the frames of the EU-supported PROFNAIT project, read more at: www.profnait.eu
View Top Employees from Prophylix ASWebsite | http://www.prophylix.com |
Revenue | $6 million |
Employees | 3 (3 on RocketReach) |
Founded | 2008 |
Address | Sykehusveien 23, Tromsø, Troms 9019, NO |
Phone | (479) 511-2385 |
Technologies | |
Industry | Biotechnology Research, Manufacturing General, Biotechnology, Manufacturing, Drug Discovery |
SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 80 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Prophylix AS employee's phone or email?
The Prophylix AS annual revenue was $6 million in 2024.
Mette Kjær is the COO of Prophylix AS.
3 people are employed at Prophylix AS.
Prophylix AS is based in Tromsø, Troms.
The NAICS codes for Prophylix AS are [3254, 325, 32].
The SIC codes for Prophylix AS are [28, 283, 80].